



ESTIMATION OF THE NUMBER OF PEOPLE WHO INJECT DRUGS AND LIVE WITH HIV AND VIRAL HEPATITIS CO-INFECTION IN UKRAINE

Dumchev K¹, Kornilova M², Saliuk T², Varetska O²

(1) Ukrainian Institute on Public Health Policy, Kyiv, Ukraine

(2) Alliance for Public Health, Kyiv, Ukraine

UIPHP UKRAINIAN INSTITUTE
ON PUBLIC HEALTH
POLICY


Disclosures

- The original study was funded by PEPFAR
- No conflict of interest to declare

UIPHP

Background

- People with triple co-morbidity including drug dependence, HIV and viral hepatitis (VH) face significant challenges in accessing life-saving treatments
- Countries with injecting drug use (IDU)-driven HIV epidemics, such as Ukraine, often lack reliable estimates to plan programs addressing these barriers



UIPHP

Methods

- Secondary analysis of data from the HIV Modes of Transmission study conducted in 2016
- Cross-sectional survey of patients registered at HIV clinics in 2013, 2014 and 2015 in 7 regions of Ukraine
- Simple random sampling
- Sensitive behavioral risk factor interview
- HCV and HBV markers testing (ARCHITECT-i1000SR Immunoassay Analyzer)

UIPHP

Prevalence of HCV and IDU in the survey

	IDU-	IDU+	
anti-HCV-	887 (71.5%) (84.9%)	158 (15.7%) (15.1%)	1045 (46.5%)
anti-HCV+	353 (28.5%) (29.4%)	849 (84.3%) (70.6%)	1202 (53.5%)
	(15.7%)	(37.8%)	
	1240 (55.2%)	1007 (44.8%)	2247

OR=13.5 (95% CI: 10.95-16.66)

UIPHP

Prevalence of HBsAg and IDU in the survey

	IDU-	IDU+	
HBsAg-	1213 (97.8%) (55.8%)	960 (95.4%) (44.2%)	2173 (96.7%)
HBsAg+	27 (2.2%) (37.0%)	46 (4.6%) (63.0%)	73 (3.3%)
	(1.2%)	(2.0%)	
	1240 (55.2%)	1006 (44.8%)	2246


OR=2.15 (95% CI: 1.33-3.49)

UIPHP


Now let's apply (with caution) these prevalences to the population of people living with HIV...

UIPHP

Estimates of HCV and drug injection among people living with HIV



Estimates of HBV and drug injection among people living with HIV



Limitations

- Some HCV-positive patients have likely underreported the IDU behavior
- Estimates are based on a survey among HIV cases registered in 2013-2015, in previous years HCV prevalence was higher

Conclusions

- The total national number of PWID with HIV/HCV coinfection may be as high as 127,000
 - Should triangulate with other data sources (2017 IBBS gives ~64,000 – see Sazonova et al abstract #364)
- As many as 75,000 of people with HIV/HCV coinfection are already in medical care, and can be easily enrolled in HCV treatment
 - At least 53,000 of them have IDU history and may require additional adherence support and harm reduction services to prevent re-infection

UIPHP

Thanks to:

- Study participants for their time
- PEPFAR for study funding
- Colleagues for contribution
- You for listening